2026
conference-abstract
OpenAlex
Sreekar Challa, Jessica D. St. Laurent, Zehra Ordulu, Alexander J. Neil et autres
Abstract The Cancer Genome Atlas (TCGA) identified four molecular subtypes of endometrial carcinoma: POLE, high microsatellite instability (MSI-H), copy number-low and copy number-high. These classifications were eventually adopted into clinical practice in the form of ProMisE, a molecular classifier for endometrial cancers …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Kristina Fanucci, Sreekar Challa, Y. Li, G. Nader-Marta et autres
Abstract Background: ILC is the second most common histologic subtype of breast cancer (BC) comprising about 15% of invasive BCs. Despite differences in clinical behavior compared to NST, patients (pts) with these histologies are treated the same. Genomic analyses may provide insights …
us
(code pays fourni par la source)
2025
article
OpenAlex
Matthew R. Nagy, Olivia Puopolo, Erin L. J. Alston, Sreekar Challa et autres
BACKGROUND: Prognostication in pediatric and young adult osteosarcoma is typically limited to metastatic status at diagnosis and tumor necrosis after chemotherapy. Despite a complex genomic landscape, few molecular biomarkers are used clinically. This study evaluates the prognostic relevance of MYC amplification and …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Chiara Corti, Sreekar Challa, Ningxuan Zhou, Alyssa R. Martin et autres
1071 Background: Guidelines define ER+ breast cancer (BC) as ≥1% tumor nuclei staining positive by IHC. Data on managing ER-low tumors (1–10% ER staining) is limited, with mixed evidence suggesting outcomes similar to ER- but a higher risk of death with adjuvant …
us, it
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Matthew R. Nagy, Olivia Puopolo, Erin L. J. Alston, Sreekar Challa et autres
10043 Background: Risk stratification in osteosarcoma relies on metastatic status and tumor necrosis after chemotherapy. Despite a complex genomic landscape, genomic biomarkers are not yet used for predicting therapy response. MYC amplification has previously been identified as a potential biomarker for chemotherapy …
us
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Varuna Shibad, Ali Bootwala, Changchuin Mao, Hanna Bader et autres
Natural IgM (nIgM) antibodies play critical roles in cancer immunosurveillance. However, the role of B-1 B cells, the lymphocytes that produce nIgM, remains to be elucidated. L2pB1 cells, a subpopulation of B-1 B cells, have a unique poly-self-reactive nIgM repertoire and are …
us
(code pays fourni par la source)